In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...

The FDA is likely to approve the first treatment for smoldering multiple myeloma but pass on a new option relapsed/refractory DLBCL, after votes by its Oncologic Drugs Advisory Committee.

For J&J, there was a positive outcome as the Oncologic Drugs Advisory Committee (ODAC) voted six to two in favour of approval ...

Roche provides update on US FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory DLBCL: Basel Thursday, May 22, 2025, 12:00 Hrs [IST] Roche ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0434 ET – Samsung Biologics is expected to sustain solid ...

As reported late last year, the AQUILA trial showed that treatment with daratumumab reduced the risk of progression to ...

The FDA’s Oncologic Drugs Advisory Committee voted against an application for Columvi (glofitamab) plus GemOx for ...

The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma ...

UK-based Juvenescence, a clinical stage AI-enabled biotech company, has secured a total of $76 million in the first-close of ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

South Korean vaccine maker SK Bioscience has secured a final court victory over US pharma major Pfizer in a long-running ...

Basel: Roche has announced that a US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) discussed ...